The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•14 April 2026•

1 min read

Goldman Sachs Lowers Tandem Target; Ex-Analyst Issues Bold XRP Forecast

Key Facts

1Goldman Sachs analyst David Roman lowered the price target for Tandem Diabetes Care (TNDM) from $28 to $25.

2An ex-Goldman Sachs analyst predicted XRP could reach $1000 by 2030, representing a 74,000% rally.

3Goldman Sachs maintained a 'Neutral' rating for TNDM despite the price target reduction.

Goldman Sachs has revised its outlook for Tandem Diabetes Care (TNDM), with analyst David Roman lowering the price target from $28 to $25. Despite the reduction, the investment bank maintained its "Neutral" rating on the stock, reflecting a more conservative stance amid margin pressure concerns. Simultaneously, a former Goldman Sachs analyst has sparked discussion in the crypto market with a speculative long-term prediction for XRP. The forecast suggests the digital asset could reach $1000 by 2030, representing a massive potential rally of 74,000%. While the TNDM adjustment reflects immediate fundamental caution regarding medical device margins, the XRP projection remains highly speculative and driven by long-term growth assumptions. These updates highlight the contrast between traditional equity valuation adjustments and high-growth speculative forecasts in the digital asset space.